Pieris secures another deal for its novel Anticalin technology – this time with Seattle in immuno-oncology.
Pieris Pharmaceuticals Inc. and Seattle Genetics Inc. have teamed up to develop bispecific immuno-oncology therapies for solid and blood cancers using both firms' core technologies, Anticalins and antibody-drug conjugates.
The idea is to develop novel antibody-anticalin fusion proteins using the core technologies of both companies: Pieris' proprietary suite of...
The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.
From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.
The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.
Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.
Evaluate’s second quarter data show that VC rounds of $100m or more totaled $2.36bn, down from $5.25bn in Q2 of 2024. Overall, the Q2 total dropped year-over-year to $4.92bn from $7.95bn.
Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.
Coartem Baby to be rolled out in eight African countries in the autumn.
